Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis

The primary hypothesis is that the co-formulation of guselkumab and golimumab (JNJ-78934804) is superior to both guselkumab and golimumab alone as measured by clinical remission at Week 48 for the treatment of participants with moderately to severely active UC who have had an inadequate initial response, loss of response, or intolerance to ≥1 ADT (defined as a biologic or a novel oral agent with biologic-like activity).